Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

copper Cu 67 ucasareotide dasaroxetan

A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional chelator 5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid (MeCOSar) and radiolabeled with the beta-emitting radioisotope copper Cu 67, with potential antineoplastic activity. Upon administration, copper Cu 67 ucasareotide dasaroxetan binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. TATE is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:67Cu-labeled MeCOSar-Tyr3-octreotate
67Cu-labelled MeCOSar-Tyr3-octreotate
copper 67 SARTATE
copper Cu 67 TATE
Copper Cu 67 Tyr3-octreotate
copper Cu 67-SARTATE
Cu-67 SARTATE
ucasareotide dasaroxetan Cu-67
Abbreviation:67Cu-SARTATE
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search